PD 1 Non Small Cell Lung Cancer Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Key Companies – Genor Biopharma, Pfizer

March 10 03:23 2023
PD 1 Non Small Cell Lung Cancer Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Key Companies - Genor Biopharma, Pfizer
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s ‘PD 1 Non Small Cell Lung Cancer Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline PD 1 Non Small Cell Lung Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD 1 Non Small Cell Lung Cancer pipeline domain.

 

PD 1 Non Small Cell Lung Cancer Overview

PD 1 is a type I transmembrane protein and is expressed on T-cells, B-cells, nature killer cells, activated monocytes, and dendritic cells (DCs). PD-L1 and PD-L2, two ligands of PD-1, are also Type I transmembrane proteins and differ in their expression patterns.

 

Some of the key takeaways from the PD 1 Non Small Cell Lung Cancer Pipeline Report:

  • Companies across the globe are diligently working toward developing novel PD 1 Non Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. PD 1 Non Small Cell Lung Cancer Key players such as – Genor Biopharma, Pfizer, GlaxoSmithKline, Arcus Biosciences, AbbVie, AstraZeneca, Biocad, Akeso Biopharma, and others, are developing therapies for the PD 1 Non Small Cell Lung Cancer treatment 
  • PD 1 Non Small Cell Lung Cancer Emerging therapies such as – PF-06801591, Prolgolimab, GB226, AZD293, Dostarlimab, AK-112, ABBV-514, Zimberelimab, and others are expected to have a significant impact on the PD 1 Non Small Cell Lung Cancer market in the coming years.
  • In February 2021, Arcus Biosciences initiated a Randomized Phase III Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
  • In May 2020, Arcus Biosciences initiated an open-label Phase II study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutic across multiple treatment arms.
  • In May 2020, Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term. Gilead gained access to Arcus’s current and future investigational immunooncology products through the agreement, as Gilead continues to expand its presence in the field.

Discover more about the emerging PD 1 Non Small Cell Lung Cancer drugs @ PD 1 Non Small Cell Lung Cancer Treatment Drugs

Emerging PD 1 Non Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include: 

  • ABBV-514: AbbVie
  • GB226: Genor Biopharma
  • Dostarlimab: GlaxoSmithKline
  • AZD2936: AstraZeneca
  • PF-06801591: Pfizer
  • Zimberelimab: Arcus Biosciences
  • AK-112: Akeso Biopharma
  • Prolgolimab: Biocad

PD 1 Non Small Cell Lung Cancer Pipeline Analysis:

The PD 1 Non Small Cell Lung Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the PD 1 Non Small Cell Lung Cancer treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD 1 Non Small Cell Lung Cancer Treatment.
  • PD 1 Non Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • PD 1 Non Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD 1 Non Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

PD 1 Non Small Cell Lung Cancer Market Drivers

  • Increase in PD 1 Non small cell lung cancer Patient Burden
  • Development of Efficient Novel Treatments
  • Increasing healthcare expenditures

PD 1 Non Small Cell Lung Cancer Market Barriers

  • Uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in Non small cell lung cancer 
  • Non small cell lung cancer with driver mutations represent a challenging population

Find out more about the PD 1 Non Small Cell Lung Cancer treatment options in development @ PD 1 Non Small Cell Lung Cancer Clinical Trials

Scope of PD 1 Non Small Cell Lung Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key PD 1 Non Small Cell Lung Cancer Companies:Genor Biopharma, Pfizer, GlaxoSmithKline, Arcus Biosciences, AbbVie, AstraZeneca, Biocad, Akeso Biopharma , and others
  • Key PD 1 Non Small Cell Lung Cancer Therapies:PF-06801591, Prolgolimab, GB226, AZD293, Dostarlimab, AK-112, ABBV-514, Zimberelimab, and others
  • PD 1 Non Small Cell Lung Cancer Therapeutic Assessment: PD 1 Non Small Cell Lung Cancer current marketed and PD 1 Non Small Cell Lung Cancer emerging therapies
  • PD 1 Non Small Cell Lung Cancer Market Dynamics:  PD 1 Non Small Cell Lung Cancer market drivers and PD 1 Non Small Cell Lung Cancer market barriers 

Table of Contents

1. Introduction

2. Executive Summary

3. PD 1 Non Small Cell Lung Cancer Overview

4. PD 1 Non Small Cell Lung Cancer Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. PD 1 Non Small Cell Lung Cancer Therapeutic Assessment

11. PD 1 Non Small Cell Lung Cancer Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. PD 1 Non Small Cell Lung Cancer Unmet Needs

14. PD 1 Non Small Cell Lung Cancer Market Drivers and PD 1 Non Small Cell Lung Cancer Market Barriers

15. Appendix

16. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com